By Fineline Cube 
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) released its Q1 2025 financial report, showing a 5.9% year-over-year (YOY) increase in revenue to RMB 133.1 million (USD 18.5 million). R&D expenses decreased by 38.8% YOY to RMB 40.4 million (USD 5.6 million), while the net loss narrowed significantly to RMB 13.5 million (USD 1.9 million) from RMB 121.5 million (USD 16.9 million) in Q1 2024. As of March 31, 2025, the company’s cash reserves stood at RMB 497.4 million (USD 69.2 million).
Business Segment Performance
In-hospital testing revenue grew 0.5% YOY to RMB 57.7 million (USD 8 million), supported by stable sales volume. Central laboratory business revenue declined by 19.6% YOY to RMB 38.3 million (USD 5.3 million), in line with the company’s strategic shift toward in-hospital diagnostics. Pharma research and development services recorded a significant 79.9% YOY increase in revenue to RMB 37.1 million (USD 5.2 million), driven by increased development and testing services and milestone achievements in multiple drug development projects.
Clinical Research Advancements
During the reporting period, Burning Rock continued to advance its clinical research in circulating tumor DNA (ctDNA) monitoring and minimal residual disease (MRD) detection. The company presented multiple study findings at the 2025 ASCO and AACR conferences, highlighting its commitment to innovation in cancer diagnostics.-Fineline Info & Tech